Stage IIIC Skin Melanoma Clinical Trial
Official title:
A Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects With Stage III Melanoma
The purpose of this study is to assess the safety, efficacy, and immunological response to
the study product, TLI, as an adjuvant therapy in subjects with Stage III Melanoma.
Normal cells in the body have an established lifespan. Cancer cells on the other hand have
the ability to continue to divide into new cells indefinitely. More than 85% of cancer has
this ability because of an enzyme found in the cancer cell. The Investigational Product,
Transgenic Lymphocyte Immunization (TLI), is aimed at helping the immune system target this
enzyme found in most cancerous cells.
Subjects who meet all inclusion and exclusion criteria will undergo a leukapheresis in which
white blood cells will be collected and used to manufacture their own personal study
product. Subjects will receive 3 infusions of TLI roughly 1 month apart and will be followed
over a 2 year period with routine laboratory draws, computed tomography (CT) scans and
physical exams.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01886235 -
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
|
N/A | |
Completed |
NCT01961115 -
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
Completed |
NCT01989559 -
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
|
Phase 1 | |
Withdrawn |
NCT02812693 -
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
|
Phase 1/Phase 2 | |
Completed |
NCT02857374 -
Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy
|
N/A | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00397982 -
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
|
Phase 2 | |
Terminated |
NCT01744171 -
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
|
Phase 1 | |
Terminated |
NCT02748564 -
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
Completed |
NCT02941744 -
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
|
Phase 1/Phase 2 | |
Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
Terminated |
NCT02327390 -
Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma
|
Phase 1 | |
Completed |
NCT03028948 -
Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma
|
N/A | |
Active, not recruiting |
NCT03719131 -
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
|
Phase 2 | |
Completed |
NCT00110019 -
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 3 | |
Completed |
NCT02320305 -
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT03112668 -
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
|
N/A | |
Completed |
NCT00019682 -
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
|
Phase 3 | |
Active, not recruiting |
NCT03154190 -
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
|
N/A |